Abstract：Objective To test the levels of interleukin-17（IL-17）and interleukin-10（IL-10）in non-small cell lung cancer（NSCLC）patients’ peripheral bloodand analyze it’s relationship with clinical staging. Methods Collected peripheral blood of 23 cases of NSCLC patients and 15 healthy volunteers in our department,segregated serum,tested the levels of IL-17 and IL-10 with ELISA,and analyzedit’s relationship with clinical stage. Results From healthy groups to III - IV stage NSCLC patients,IL-17 levels werereduceingcontinually,and the levels of III-IV stage patients were lesser than healthy volunteers obviously,the difference was statistical significant（P<0.05）,however,there were no obvious difference between healthy volunteersand I-II stage patients、I-II stage and III-IV stage patients;III-IV stage patients’ IL-10 levels were higher than another two groups,the difference wasstatistical significant（P<0.05）,there were no obvious difference betweenhealthy volunteers and I-II stage patients. Conclusion IL-17 and IL-10 is participating in the occurrence and development of NSCLC,IL-17 and IL-10 may plays antitumor and promote tumor effect,respectively.
马维江, 刘鑫, 杨立民, 杨震, 和濛. IL-17和IL-10在NSCLC患者外周血中含量的检测及其临床意义[J]. 哈尔滨医药, 2022, 42(4): 1-2.
Ma Weijiang, Liu Xin, Yang Limin, Yang Zhen, He Meng. To Test Levels of IL-17 and IL-10 in NSCLC Patients’ Peripheral Blood and Its Clinical Significance. journal1, 2022, 42(4): 1-2.
[1] Miller KD,Goding Sauer A,Ortiz AP,et al.Cancer Statistics for Hispanics/Latinos,2018[J].CA Cancer J Clin,2018,68(6):425-445. [2] 孙立春,李丹丹,李净,等.CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J].实用肿瘤学杂志,2019,33(3): 215-221. [3] Zhou Y,Yang X,Zhang H,et al.The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats[J].Transplantation,2015,99(6):1126-31. [4] Hirahara K,Ghoreschi K,Laurence A,et al.Signal transduction pathways and transcriptional regulation in Th17 cell differentiation[J].Cytokine Growth Factor Rev,2010,21(6): 425-434. [5] Wang Y,Xing F,Ye S,et al.Jagged-1 signaling suppresses the IL-6 and TGF-β treatment-induced Th17 cell differentiation via the reduction of RORγt/IL-17A/IL-17F/IL-23a/IL-12rb1[J].Sci Rep,2015,5:8234. [6] Huang Q,Duan L,Qian X,et al.IL-17 Promotes Angiogenic Factors IL-6,IL-8,and Vegf Production via Stat1 in Lung Adenocarcinoma[J].Sci Rep,2016,6:36551. [7] Chen Z,Ding J,Pang N,et al.The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients[J].Diagn Pathol,2013,8:61. [8] Benatar T,Cao MY,Lee Y,et al.IL-17E,a proinflammatory cytokine,has antitumor efficacy against several tumor types in vivo[J].Cancer Immunol Immunother,2010,59(6):805-817.
2022, Vol. 42 
